Insulin-stimulated mTOR activation in peripheral blood mononuclear cells associated with early treatment response to lithium augmentation in rodent model of antidepressant-resistance
Open Access
- 15 March 2019
- journal article
- research article
- Published by Springer Nature in Translational Psychiatry
- Vol. 9 (1) , 1-11
Abstract
Lithium has been shown to have some therapeutic efficacy as an adjunctive treatment for intractable forms of major depression. Activation of mammalian target of rapamycin (mTOR) and inhibition of glycogen synthase kinase-3β (GSK3β) have been implicated in its putative mechanisms of action. These proteins are integral components of the insulin signaling pathway, which may serve as a critical co-regulator of drug action. Utilizing an animal model of tricyclic antidepressant resistance, we investigated the relationship between insulin signaling and antidepressant response to lithium augmentation. Pre-treatment with adrenocorticotropic hormone (ACTH 100 µg/day i.p.) for 14 days effectively blocked the immobility-reducing effects of an acute dose of imipramine (10 mg/kg i.p.) in the forced swim test (FST). Lithium augmentation (100 mg/kg i.p.) rescued the antidepressant-like effects of imipramine in this model. Total and phosphorylated (p) levels of protein kinase B (Akt), mTOR, and GSK3β protein were quantified in the infralimbic cortex (ILPFC) following FST stress via Western blot. Levels of mTOR and pmTOR were further quantified in isolated peripheral blood mononuclear cells (PBMCs) following insulin stimulation (10 mg/mL for 5 min) via ELISA. Elevated levels of phosphorylated insulin signaling proteins were present in the ILPFC of ACTH-pretreated animals that received both imipramine and lithium, together with a concurrent increase in mTOR activation in PBMCs. Large correlations were observed between immobility time and insulin-stimulated mTOR levels in PBMCs. We propose that PBMC insulin challenge may be a useful probe for predicting antidepressant response to lithium administration, and potentially other therapies acting via similar mechanisms of action.Keywords
Funding Information
- Deakin University
This publication has 45 references indexed in Scilit:
- Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistanceBehavioural Brain Research, 2015
- Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorderEuropean Neuropsychopharmacology, 2015
- Influence of mTOR in energy and metabolic homeostasisMolecular and Cellular Endocrinology, 2014
- Glucagon-like peptide-2 but not imipramine exhibits antidepressant-like effects in ACTH-treated miceBehavioural Brain Research, 2013
- Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levelsBehavioural Brain Research, 2013
- Potential Mechanisms of Action of Lithium in Bipolar DisorderCNS Drugs, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Protein levels of β-catenin and activation state of glycogen synthase kinase-3β in major depression. A study with postmortem prefrontal cortexJournal of Affective Disorders, 2012
- Rodent Models of Depression: Forced Swim and Tail Suspension Behavioral Despair Tests in Rats and MiceCurrent Protocols in Pharmacology, 2010
- Lithium and the structure of exploratory behavior in the ratProgress in Neuro-Psychopharmacology, 1980